Janux Therapeutics/$JANX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Janux Therapeutics
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Ticker
$JANX
Sector
Primary listing
Employees
103
Headquarters
Website
JANX Metrics
BasicAdvanced
$1.5B
-
-$1.80
2.85
-
Price and volume
Market cap
$1.5B
Beta
2.85
52-week high
$64.87
52-week low
$21.73
Average daily volume
906K
Financial strength
Current ratio
47.035
Quick ratio
46.854
Long term debt to equity
2.051
Total debt to equity
2.24
Profitability
EBITDA (TTM)
-142.797
Gross margin (TTM)
-15,478.13%
Net profit margin (TTM)
-24,064.01%
Operating margin (TTM)
-33,002.05%
Management effectiveness
Return on assets (TTM)
-10.51%
Return on equity (TTM)
-12.82%
Valuation
Price to revenue (TTM)
3,276.185
Price to book
1.46
Price to tangible book (TTM)
1.46
Price to free cash flow (TTM)
-23.693
Free cash flow yield (TTM)
-4.22%
Free cash flow per share (TTM)
-1.032
Growth
Revenue change (TTM)
-97.10%
Earnings per share change (TTM)
99.84%
3-year revenue growth (CAGR)
-59.74%
3-year earnings per share growth (CAGR)
10.96%
What the Analysts think about JANX
Analyst ratings (Buy, Hold, Sell) for Janux Therapeutics stock.
Bulls say / Bears say
In August 2025, Janux received a $10 million milestone payment from Merck after dosing the first patient in its TRACTr collaboration, which validates its technology platform and provides non-dilutive capital (SEC)
As of June 30, 2025, Janux held $996 million in cash and short-term investments, giving it more than a year's operational runway with its current rate of spending (Reuters)
Wall Street analysts have a “buy” consensus rating with a median 12-month price target of $76, representing about 68% potential upside from current levels (Reuters)
Janux reported a net loss of $33.9 million for the second quarter, a significant increase from $6.0 million in Q2 2024, indicating a faster rate of cash burn (Reuters)
The company posted zero GAAP revenue in Q2, falling short of analyst expectations of $0.25 million and down from $8.9 million a year ago, highlighting its absence of commercial products (Nasdaq)
Both leading drug candidates, JANX007 and JANX008, are still in Phase 1 trials, with no new clinical data shared in Q2, leaving Janux exposed to substantial clinical and regulatory risk (The Motley Fool via Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.
JANX Financial Performance
Revenues and expenses
JANX Earnings Performance
Company profitability
JANX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Janux Therapeutics stock?
Janux Therapeutics (JANX) has a market cap of $1.5B as of October 25, 2025.
What is the P/E ratio for Janux Therapeutics stock?
The price to earnings (P/E) ratio for Janux Therapeutics (JANX) stock is 0 as of October 25, 2025.
Does Janux Therapeutics stock pay dividends?
No, Janux Therapeutics (JANX) stock does not pay dividends to its shareholders as of October 25, 2025.
When is the next Janux Therapeutics dividend payment date?
Janux Therapeutics (JANX) stock does not pay dividends to its shareholders.
What is the beta indicator for Janux Therapeutics?
Janux Therapeutics (JANX) has a beta rating of 2.85. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.